Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 574,602
  • Shares Outstanding, K 26,763
  • Annual Sales, $ 17,160 K
  • Annual Income, $ -163,620 K
  • 60-Month Beta -0.30
  • Price/Sales 33.29
  • Price/Cash Flow N/A
  • Price/Book 6.42
Trade ANAB with:

Options Overview Details

View History
  • Implied Volatility 83.24% ( +8.94%)
  • Historical Volatility 80.36%
  • IV Percentile 79%
  • IV Rank 51.21%
  • IV High 117.58% on 09/19/23
  • IV Low 47.19% on 07/25/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 1,414
  • Open Int (30-Day) 1,384

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.56
  • Number of Estimates 6
  • High Estimate -1.42
  • Low Estimate -1.90
  • Prior Year -1.58
  • Growth Rate Est. (year over year) +1.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.78 +0.23%
on 04/18/24
25.62 -22.60%
on 04/11/24
-3.34 (-14.42%)
since 03/18/24
3-Month
19.78 +0.23%
on 04/18/24
27.50 -27.89%
on 02/26/24
-3.86 (-16.29%)
since 01/18/24
52-Week
13.36 +48.43%
on 11/28/23
27.50 -27.89%
on 02/26/24
-2.41 (-10.84%)
since 04/18/23

Most Recent Stories

More News
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

A powerfully bullish new analyst take on the company helped it rally on the market.

WFC : 58.74 (+2.73%)
LLY : 745.95 (-0.64%)
ANAB : 19.83 (-7.64%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 358.41 (-2.13%)
ABBV : 164.66 (+0.25%)
ABCL : 3.91 (-0.26%)
ALNY : 145.16 (-0.11%)
AMGN : 262.75 (-0.50%)
ANAB : 19.83 (-7.64%)
AZN : 68.36 (-0.25%)
BMY : 48.30 (+0.96%)
INCY : 52.82 (+0.19%)
REGN : 893.99 (-0.80%)
VIE : 53.01 (unch)
Wall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should Know

The consensus price target hints at a 45.1% upside potential for AnaptysBio, Inc. (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

ANAB : 19.83 (-7.64%)
CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock?

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

CRSP : 56.16 (+1.08%)
ANAB : 19.83 (-7.64%)
GSK's Jemperli Effective Against First-Line Endometrial Cancer

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

GSK : 39.27 (-0.83%)
MRK : 125.23 (-0.11%)
ANAB : 19.83 (-7.64%)
CERT : 16.21 (-4.37%)
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANAB : 19.83 (-7.64%)
ALGS : 0.7931 (+0.78%)
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 72.00 (-6.12%)
ANAB : 19.83 (-7.64%)
Cytek Biosciences, Inc. (CTKB) Q4 Earnings Top Estimates

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 40% and 3.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CTKB : 5.96 (+0.68%)
ANAB : 19.83 (-7.64%)
Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 17.24% and 0.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

RGEN : 157.06 (-2.44%)
ANAB : 19.83 (-7.64%)
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ANAB : 19.83 (-7.64%)
CLSD : 1.3200 (+4.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 23.14
2nd Resistance Point 22.46
1st Resistance Point 21.15
Last Price 19.83
1st Support Level 19.15
2nd Support Level 18.47
3rd Support Level 17.15

See More

52-Week High 27.50
Fibonacci 61.8% 22.10
Fibonacci 50% 20.43
Last Price 19.83
Fibonacci 38.2% 18.76
52-Week Low 13.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar